NATx0

NATx0 (2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-ol) is a novel, water-soluble electrophilic nitroalkene derivative of Trolox, which is a hydrophilic analogue of Vitamin E. It is being developed as a multi-target anti-inflammatory and metabolic modulator for the treatment of chronic inflammatory conditions, including obesity, glucose intolerance, and atherosclerosis. NATx0 functions through a pleiotropic mechanism of action: it covalently modifies specific protein thiols via Michael addition, leading to the inhibition of the **NF-κB** signaling pathway (by blocking p65 nuclear translocation) and the **NLRP3 inflammasome** (by preventing ASC oligomerization). Simultaneously, it activates the **Nrf2/Keap1** antioxidant response and acts as an agonist for **PPARγ**. These combined actions result in a significant reduction of pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα. Preclinical studies in diet-induced obese mice have shown that NATx0 administration improves glucose homeostasis and reduces muscle tissue inflammation, highlighting its potential for managing metabolic syndrome and type 2 diabetes.

Other names

nitroalkene-Trolox derivative2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-ol